About EirGenix
EirGenix is a company based in Taipei (Taiwan) founded in 2012. EirGenix has raised $90.58 million across 2 funding rounds from investors including CDIB Capital Group. EirGenix operates in a competitive market with competitors including KBI Biopharma, Aldevron, Arranta Bio, Ovagen and IDT Biologika, among others.
- Headquarter Taipei, Taiwan
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eirgenix, Inc.
-
Annual Revenue
$1.01 B-1.34as on Dec 31, 2024
-
Net Profit
-$698.34 M23.7as on Dec 31, 2024
-
EBITDA
-$652.23 M17.77as on Dec 31, 2024
-
Total Equity Funding
$90.58 M (USD)
in 2 rounds
-
Latest Funding Round
$90.58 M (USD), Series B
Sep 22, 2021
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of EirGenix
EirGenix is a publicly listed company on the TWSE with ticker symbol 6589 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of EirGenix
Unlock access to complete
Unlock access to complete
Funding Insights of EirGenix
EirGenix has successfully raised a total of $90.58M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $90.58 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in EirGenix
EirGenix has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CDIB Capital Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic investments are made in early-stage Asia Pacific startups.
|
Locked | Locked | Locked |
Investor details for EirGenix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EirGenix
Investment portfolio details for EirGenix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - EirGenix
Detailed financials for EirGenix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eirgenix Comparisons
Peer comparison for EirGenix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of EirGenix
EirGenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, Aldevron, Arranta Bio, Ovagen and IDT Biologika, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of protein formulation, process & cell line development, and cGMP services
|
|
| Locked | Locked | Locked |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| Locked | Locked | Locked |
Developer of therapeutics for microbiome based diseases
|
|
| Locked | Locked | Locked |
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services
|
|
| Locked | Locked | Locked |
Vaccines and biologics are developed and manufactured by IDT Biologika.
|
Detailed competitors of EirGenix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eirgenix
Complete news archive for EirGenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EirGenix
EirGenix was founded in 2012 and raised its 1st funding round 6 years after it was founded.
EirGenix is headquartered in Taipei, Taiwan.
Lee Cheng Liu is the current CEO of EirGenix.
EirGenix is a funded company, having raised a total of $90.58M across 2 funding rounds to date.
EirGenix was founded in 2012 in Taipei, Taiwan, as a contract development and manufacturing organization focused on biologics. Services include cell line development for mammalian systems, analytical testing, and cGMP manufacturing from pre-clinical to commercial phases. Process development spans shake flasks to 100L bioreactors for mammalian cells and up to 20L fermentors for microbial cells. Downstream purification services are provided for both mammalian and microbial platforms.
EirGenix's top competitors include KBI Biopharma, Aldevron and Ovagen.
Yes, EirGenix is publicly traded on TWSE under the ticker symbol 6589.
EirGenix has 1 investor. Key investors include CDIB Capital Group.
The ticker symbol of EirGenix is 6589 on TWSE.